Headquartered in Boston, MA Fiscal year ends December NASDAQ: CMPX compasstherapeutics.com
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Its pipeline includes tovecimig (DLL4 x VEGF-A bispecific antibody) being advanced toward a potential BLA filing for biliary tract cancer, CTX-8371 (PD-1 x PD-L1 bispecific antibody) in Phase 1 cohort expansions across triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, CTX-10726 (PD-1 x VEGF-A bispecific antibody) in Phase 1 dose escalation, and CTX-471 (CD137 agonist antibody) entering Phase 2 for tumors expressing NCAM (CD56). The company designs product candidates to target multiple critical biological pathways required for an effective anti-tumor response, including modulation of the microvasculature via angiogenesis-targeted agents, induction of immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass trades on the Nasdaq under the ticker CMPX. Updated
Pre-Market Stock Futures: Futures are trading lower on Wednesday after an ADP report showing job losses, following a stellar day across Wall Street on Tuesday. All of the major indices finished the…
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth.
The Wall Street consensus 12-month price target for CMPX is $5.45.
